European fund opportunities: monetary and fiscal stimulus supports JEDT’s outperformance

JEDT

JPMorgan European Discovery Trust plc (LON:JEDT) has released its latest factsheet.

Month in review as of 31/01/2026

  • The trust outperformed the benchmark over January.
  • At the stock level, our overweight position in Danieli, one of the largest suppliers of plants and equipment to the metals industry, contributed to performance given continued strong order momentum.
  • Our overweight position in Kitron, a leading electronic manufacturing services (EMS) provider also contributed to performance due to a positive defence exposure and outlook, as well as the closing of a notable acquisition.
  • Our overweight position in Unipol, a leading Italian insurance company, detracted from performance due to general weakness across the insurance sector, as well as concerns over self-driving vehicles reducing demand for motor insurance over the longer-term.
  • Our overweight position in Temenos, a banking software provider, also detracted from performance due to general negative sentiment towards software companies given the disruptive threat of AI.

Looking ahead as of 31/01/2026

  • Europe has been and should continue to be a beneficiary of monetary stimulus. The eurozone is still an economy sensitive to short-term interest rates, and past rate cuts continue to support credit growth.
  • Fiscal stimulus has also contributed to the strong performance of southern Europe, which has benefited significantly from the EU’s Recovery Fund.
Share on:

Latest Company News

Genflow Biosciences reports early findings from SIRT6 gene therapy study

Genflow Biosciences reports early findings from its SIRT6 gene therapy study in older dogs, with further monitoring planned over...

Ilika CEO to discuss battery gigafactory development at Barcelona industry forum

Ilika CEO Graeme Purdy is set to speak at the December 2026 Barcelona battery gigafactory forum, bringing the company's...

Investors demand clear returns as AI spending comes under scrutiny

Investors are demanding clearer returns from AI spending as technology shares face pressure, with corporate earnings, data centre investment...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

itim Group targets retail AI market with new platform launch

ITIM Group is targeting the retail AI market with itimAIQ, a new platform designed to automate operations, improve efficiency...

Drax sets date for 2026 Capital Markets Day and trading update

Drax Group will host its Capital Markets Day on 23 November 2026, providing investors and analysts with a management...

    Search